Drug Information

Drug General Information
Drug ID
D0F9BT
Former ID
DIB001224
Drug Name
ONX-0912
Synonyms
PR-047; PR-141; PR-924; PR-928; Proteasome inhibitor (oral, cancer), Proteolix Inc/Onyx Pharmaceuticals Inc; Proteasome inhibitor program (oral, cancer), Onyx Pharmaceuticals/Ono Pharmaceutical
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Preclinical [548643]
Company
Onyx pharmaceuticals
Formula
C25H32N4O7S
Canonical SMILES
s1c(ncc1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)[C@]1(<br />CO1)C)Cc1ccccc1)COC)COC)C
PubChem Compound ID
25067547
Target and Pathway
Target(s) Proteasome Target Info Modulator [531139]
References
Ref 548643Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027317)
Ref 531139A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 2;116(23):4906-15.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.